Cite
The Clinical Impact of [68Ga]‐DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours.
MLA
Wannachalee, Taweesak, et al. “The Clinical Impact of [68Ga]‐DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours.” Clinical Endocrinology, vol. 91, no. 2, Aug. 2019, pp. 288–94. EBSCOhost, https://doi.org/10.1111/cen.14008.
APA
Wannachalee, T., Turcu, A. F., Bancos, I., Habra, M. A., Avram, A. M., Chuang, H. H., Waguespack, S. G., & Auchus, R. J. (2019). The Clinical Impact of [68Ga]‐DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours. Clinical Endocrinology, 91(2), 288–294. https://doi.org/10.1111/cen.14008
Chicago
Wannachalee, Taweesak, Adina F. Turcu, Irina Bancos, Mouhammed Amir Habra, Anca M. Avram, Hubert H. Chuang, Steven G. Waguespack, and Richard J. Auchus. 2019. “The Clinical Impact of [68Ga]‐DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours.” Clinical Endocrinology 91 (2): 288–94. doi:10.1111/cen.14008.